Theatre numbers up but less new plays, study says

UK theatre attendances rose 6.1% in 2023 versus 2019 despite 9.9% fewer shows and 11.6% fewer performances, the British Theatre Consortium reports. New play openings fell ~30% while musical theatre expanded its share — performances from ~33% to 40%, attendances from ~50% to over half, and box office income from ~60% to nearly 66% — with new musicals rising from 37% new in 2019 to just over 50% in 2023 and accounting for 56% of box office takings for new work. Producers report commercial caution around new plays, suggesting a continued market tilt toward proven, revenue-generating musicals and collaborative production models to de-risk new drama.

Analysis

Market structure: The data show a concentration: attendances rose +6.1% while overall shows fell -9.9% and performances -11.6%, with musical theatre increasing to ~40% of performances and ~66% of box office (from ~60%). Winners are large commercial IP-backed producers, ticketing platforms and venue owners that can scale musicals and premium pricing; losers are regional/new-play specialists and drama-heavy producers with thin commercial margins.

Risk assessment: Short-term (days–weeks) risk is headline-driven (award/transfer news, strike threats); medium-term (months) risks include financing cost rises compressing producer margins and labour/union action; long-term (quarters–years) tail risks are another pandemic wave or an oversupply of musicals that compresses yields. Hidden dependency: not-for-profit incubators are quietly de-risking pipeline — public funding or charity underwriting could re-price risk for commercial producers.

Trade implications: Prefer exposure to large ticketing/live-event platforms and IP owners (themes: scale, pricing power, secondary ticketing) and de-emphasise small, drama-dependent operators. Options: use 9–18 month call spreads to capture gradual secular reallocation to musicals while capping premium. Catalyst triggers to watch: West End transfers, S1 box-office disclosures, and UK arts funding announcements in next 3–6 months.

Contrarian angle: The market may under-price saturation risk — an influx of new musicals (new-musical share rose from 37% to >50%) could lead to ticketing margin compression and consumer fatigue in 12–24 months. Conversely, partnerships between commercial producers and NFPs create a stealth subsidy that could reflate returns for new-play incubations earlier than consensus expects.

Key Decisions for Investors

• Establish a 1.5–2.0% long position in Live Nation Entertainment (LYV) within 4 weeks to capture global live-ticketing upside from musical-driven box office; implement via a 12–18 month call spread (buy ATM call, sell ~+40% OTM) to limit premium; set a tactical target of +25–40% and hard stop at -20% or 12 months.
• Add a 0.5–1.0% position in CTS Eventim (EVD.DE) within 60 days (outright or 9–12 month call spread ATM→+30% OTM) to get European theatre/musicals exposure; exit if EU box-office volumes fall to >5% below 2019 baseline in any rolling quarter.
• Deploy a 0.75–1.0% position via Disney (DIS) 9–12 month call spread to play IP-to-stage monetisation (expect licensing/transfers as catalysts); take profits if DIS moves +30% or if no major stage licensing announcements occur within 6 months.
• Execute a relative-value pair: long LYV (1.5%) / short Eventbrite (EB) (1.0%) to express preference for large-scale commercial musicals over local-event platforms; review after 90 days and rebalance if pair performance diverges >15%.
• Trim 30–50% of existing allocations to UK small-cap leisure/regional theatre-exposed holdings (if held) over the next 8 weeks and redeploy proceeds into LYV/EVD.DE/DIS trades to reduce idiosyncratic new-play risk and concentration in drama-dependent balance sheets.